Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,515.00
-25.00 (-0.98%)
At close: May 13, 2025, 3:30 PM KST
-29.94%
Market Cap 78.18B
Revenue (ttm) 27.74B
Net Income (ttm) -20.11B
Shares Out 31.09M
EPS (ttm) -660.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 93,208
Average Volume 250,850
Open 2,560.00
Previous Close 2,540.00
Day's Range 2,510.00 - 2,590.00
52-Week Range 2,170.00 - 7,335.00
Beta 1.29
RSI 41.97
Earnings Date May 14, 2025

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, co... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 314130
Full Company Profile

Financial Performance

In 2024, Genome & Company's revenue was 27.74 billion, an increase of 94.07% compared to the previous year's 14.30 billion. Losses were -20.11 billion, -57.63% less than in 2023.

Financial Statements

News

There is no news available yet.